Northstar Response®
Pan-cancer liquid biopsy for treatment response monitoring
Approved/CommercialMarketed
Key Facts
Indication
Pan-cancer liquid biopsy for treatment response monitoring
Phase
Approved/Commercial
Status
Marketed
Company
About BillionToOne
BillionToOne is a commercial-stage molecular diagnostics company leveraging its Quantitative Counting Templates™ (QCTs™) technology to achieve single-molecule resolution in genetic testing. Founded in 2016, the company has launched two main product lines: UNITY Complete® for comprehensive prenatal screening and the Northstar platform for oncology liquid biopsy. Having completed an upsized IPO in late 2025, BillionToOne is now a public company executing on its vision to make precise, quantitative diagnostics more accessible.
View full company profile